Vicarious Surgical Completes Integrated Benchtop Testing of Full Surgical Instrument Suite for Ventral Hernia Repair
Rhea-AI Summary
Vicarious Surgical (OTCQB: RBOT) completed integrated benchtop testing of its full surgical instrument suite for ventral hernia repair, validating needle drivers, fenestrated graspers, and monopolar scissors in a unified system evaluation.
Instrument and camera sensors remained stable under monopolar electrosurgical energy, supporting the company’s move toward design freeze and planned preclinical cadaveric and porcine studies.
Positive
- Completed integrated benchtop testing of the full three-instrument suite
- Monopolar scissors showed strong motion and mechanical cutting after automated calibration
- Instrument and camera sensors remained stable under monopolar electrosurgical energy
Negative
- Results are preclinical; no first-in-human or clinical use yet
- Company must still complete cadaveric and porcine studies before clinical readiness
- Design freeze remains a target milestone, not yet achieved
Key Figures
Market Reality Check
Peers on Argus
RBOT was down 16.47% while peers were mixed: IINN (-21.38%), ECOR (-2.49%), MODD (-4.91%), NMTC (-3.46%), MYO (+2.88%). Scanner momentum only flagged MODD on the upside, pointing to stock-specific pressure for RBOT rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 25 | OTCQB quotation | Positive | -5.6% | Shift to OTCQB trading as step toward potential Nasdaq listing. |
| Mar 16 | Nasdaq plan | Positive | +29.4% | Strategic plan to strengthen finances and pursue Nasdaq relisting. |
| Mar 09 | Earnings update | Positive | +24.3% | Reported lower operating expenses, narrower losses, and lower 2026 cash burn. |
| Mar 04 | NYSE delisting | Negative | -53.2% | Received NYSE delisting notice after failing market cap listing standard. |
| Jan 12 | Porcine lab data | Positive | +2.3% | Successful in-vivo porcine lab advancing system toward design freeze. |
News reactions have mostly aligned with the underlying sentiment, with only one recent divergence where seemingly positive capital-markets news coincided with a negative price move.
Over the past few months, RBOT has combined development milestones with capital-markets restructuring. A January 12 porcine lab success and the new benchtop testing both support its ventral hernia repair program and progress toward design freeze by end of 2026. Meanwhile, a March 4 NYSE delisting notice and subsequent March 16 and March 25 actions laid out a path toward a potential Nasdaq listing via OTC quotation and strategic financing. Today’s system-level instrument testing fits into this ongoing push toward clinical readiness and relisting eligibility.
Regulatory & Risk Context
An effective S-3 shelf filed on 2025-12-12 allows the company to offer up to $100,000,000 in various securities, including an at-the-market program for up to $3,000,000 of Class A common stock through H.C. Wainwright & Co., providing flexibility to raise capital that could be dilutive to existing holders if utilized.
Market Pulse Summary
This announcement details successful integrated benchtop testing of RBOT’s full surgical instrument suite for ventral hernia repair, reinforcing prior porcine lab progress and moving the system closer to design validation and first-in-human use. Recent history shows parallel tracks: steady technical advancement and active capital-markets work around relisting and financing. Investors may monitor execution toward design freeze, upcoming cadaveric and porcine studies, and any utilization of the $100,000,000 shelf or other funding tools as key markers of future dilution and development risk.
Key Terms
ventral hernia repair medical
benchtop testing technical
monopolar scissors medical
AI-generated analysis. Not financial advice.
WALTHAM, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB: RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the “Company”), today announced the successful completion of initial integrated benchtop testing for its full suite of surgical instruments, required for its anticipated first clinical indication of ventral hernia repair, marking an important step toward design validation, clinical readiness, and the Company’s targeted design freeze milestone.
This milestone represents the first system-level performance evaluation of the Company's three core instruments: needle drivers, fenestrated graspers, and monopolar scissors, each of which is designed for use with the Vicarious Surgical System. The successful testing of all three instruments in a unified evaluation serves as a critical step in systematically de-risking the Company's path toward first-in-human use.
Notably, the monopolar scissors, which previously demonstrated successful electrical performance in a December porcine lab study, exhibited strong motion and mechanical cutting capabilities following the Company's standard automated calibration and bring-up process. Importantly, instrument and camera sensors remained stable, with no degradation in video or motion quality in the presence of monopolar electrosurgical energy, confirming robust system performance under clinically relevant operating conditions.
"This milestone represents an important step in systematically de-risking our system as we advance toward design freeze and first-in-human use," said Stephen From, Chief Executive Officer of Vicarious Surgical. "Demonstrating reliable, integrated performance across our full instrument suite, including stability under electrosurgical energy, reinforces our confidence in the system architecture and our development timeline. Each successful test brings us closer to enabling a new standard in minimally invasive robotic surgery."
The successful completion of this benchtop testing positions the Company to advance to the next phase of preclinical validation, including planned cadaveric and porcine studies, as it continues to prepare for first clinical use of the Vicarious Surgical System and execute against a defined series of development milestones leading to design freeze.
About Vicarious Surgical
Founded in 2014, Vicarious Surgical is a next-generation surgical robotics company, developing a unique disruptive technology with the multiple goals of substantially increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company’s novel surgical approach uses proprietary human-like surgical robots to virtually transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced team of technologists, medical device professionals and physicians, and has received backing by technology luminaries including Bill Gates, Vinod Khosla’s Khosla Ventures, Innovation Endeavors, Jerry Yang’s AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang’s E15 VC. The Company is headquartered in Waltham, Massachusetts. Learn more at www.vicarioussurgical.com.
In accordance with guidance provided by the SEC regarding use by a company of its websites and social media channels as a means to disclose material information to investors and to comply with its disclosure obligations under Regulation FD, the Company hereby notifies investors, the media and other interested parties that it intends to continue to use its investor relations website (https://investor.vicarioussurgical.com/), its LinkedIn page (https://linkedin.com/company/vicarious-surgical/) and its X feed (@VicariousSurg) to publish important information about the Company, including information that may be deemed material to investors. The list of social media channels that the Company uses may be updated on its investor relations website from time to time. The Company encourages investors, the media, and other interested parties to review the information the Company posts on its website and social media channels as described above, in addition to information announced by the Company through its SEC filings, press releases and public conference calls and webcasts.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The Company’s actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical facts contained herein, including without limitation, statements regarding the anticipated first clinical indication, the ability to de-risk the pathway towards first-in-human use, and the development timeline for the Vicarious Surgical System, including development milestones and design freeze, are forward-looking statements that reflect the current beliefs and expectations of management. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the Company’s ability to obtain and maintain listing on a national securities exchange; the impacts of the Company’s reduced cash burn; the price of the Class A common stock following any reverse stock split; the Company’s future business strategy; the approval, commercialization and adoption of the Company’s initial product candidates and the success of its single-port surgical robot, called the Vicarious Surgical System, and any of its future product candidates and service offerings; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product and service development activities; the potential attributes and benefits of the Company’s product candidates and services; the Company’s ability to obtain and maintain regulatory approval for the Vicarious Surgical System, and any related restrictions and limitations of any approved product; the size and duration of human clinical trials for the Vicarious Surgical System; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing license, manufacture, supply and distribution agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company’s product candidates and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s product candidates and services and reimbursement for medical procedures conducted using its product candidates and services; the company’s estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company’s financial performance; economic downturns, political and market conditions and their potential to adversely affect the Company’s business, financial condition and results of operations; the Company’s intellectual property rights and its ability to protect or enforce those rights, and the impact on its business, results and financial condition if it is unsuccessful in doing so; and other risks and uncertainties indicated from time to time in the Company’s filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
Investor Contact
ir@vicarioussurgical.com
Media Inquiries
media@vicarioussurgical.com
Source: Vicarious Surgical Inc.
FAQ
What did Vicarious Surgical (RBOT) achieve on March 30, 2026 regarding benchtop testing?
How did the monopolar scissors perform in RBOT's integrated benchtop tests?
Did Vicarious Surgical report any sensor or video degradation during electrosurgical testing?
What are the next development steps for RBOT after this benchtop milestone?
Does the benchtop testing mean Vicarious Surgical is ready for first-in-human use?
How does this milestone affect Vicarious Surgical's design freeze timeline for RBOT?
